Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo New Product Program, Quality Control Back On Track In FY 2002

This article was originally published in The Tan Sheet

Executive Summary

Corrective actions taken in response to an unfavorable FDA inspection of Perrigo's Allegan, Mich. facility will preclude the planned November launch of minoxidil 5% and stall the company's pipeline, Perrigo told analysts in an Oct. 25 conference call.
Advertisement

Related Content

Perrigo Vitamin Sales Jump 20%, OTCs Up 13% In Fiscal First Quarter
Perrigo Vitamin Sales Jump 20%, OTCs Up 13% In Fiscal First Quarter
Perrigo Vitamin Sales Jump 20%, OTCs Up 13% In Fiscal First Quarter
Perrigo Multiple Acquisitions Expected In Next 12 Months - CEO Gibbons
Minoxidil
Perrigo Indication-Specific Analgesics Slated For Mid-2001 Launch
Pharmacia
Perrigo Extended-Release Acetaminophen Launch Delayed By QC Issues
Leiner OTC Sales Buoy Company Performance As Supplement Market Slows
Leiner OTC Sales Buoy Company Performance As Supplement Market Slows

Topics

Advertisement
UsernamePublicRestriction

Register

PS091830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel